These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38634358)

  • 1. Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
    Beswick DM; Liu CM; Overdevest JB; Zemke A; Khatiwada A; Gudis DA; Miller JE; Kimple A; Tervo JP; DiMango E; Goralski JL; Keating C; Senior B; Stapleton AL; Eshaghian PH; Mace JC; Markarian K; Alt JA; Bodner TE; Chowdhury NI; Getz AE; Hwang PH; Khanwalker A; Lee JT; Li DA; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Turner GA; Wang MB; Saavedra MT; Taylor Cousar JL
    Laryngoscope; 2024 Sep; 134(9):3965-3973. PubMed ID: 38634358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
    Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
    McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Lynch DA; Taylor-Cousar JL
    Ann Am Thorac Soc; 2022 Jan; 19(1):12-19. PubMed ID: 34436985
    [No Abstract]   [Full Text] [Related]  

  • 7. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
    Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
    Microbiol Spectr; 2024 Aug; 12(8):e0078724. PubMed ID: 38916354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perspectives on chronic rhinosinusitis in cystic fibrosis: Symptom prioritization in the era of highly effective modulator therapy.
    Liu CM; Han EJ; Fischer JL; Mace JC; Mattos JL; Markarian K; Alt JA; Bodner TE; Chowdhury NI; Eshaghian PH; Getz AE; Hwang PH; Khanwalkar A; Kimple AJ; Lee JT; Li DA; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Turner GA; Wang MB; Taylor-Cousar JL; Saavedra MT; Beswick DM
    Int Forum Allergy Rhinol; 2024 Aug; 14(8):1282-1293. PubMed ID: 38343143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.
    DiMango E; Spielman DB; Overdevest J; Keating C; Francis SF; Dansky D; Gudis DA
    Int Forum Allergy Rhinol; 2021 Jan; 11(1):75-78. PubMed ID: 32985756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The criteria for chronic rhinosinusitis in children with cystic fibrosis are rarely fulfilled after initiation of CFTR modulator treatment.
    Bech M; Skov M; Andersen ISB; von Buchwald C; Aanæs K
    APMIS; 2024 Sep; 132(9):625-631. PubMed ID: 38773823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy.
    Beswick DM; Humphries SM; Balkissoon CD; Strand M; Vladar EK; Ramakrishnan VR; Taylor-Cousar JL
    J Cyst Fibros; 2022 Mar; 21(2):e141-e147. PubMed ID: 34598881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients.
    Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L
    Rhinology; 2024 Aug; 62(4):457-465. PubMed ID: 38530204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that predict pursuing sinus surgery in the era of highly effective modulator therapy.
    Beswick DM; Han EJ; Mace JC; Markarian K; Alt JA; Bodner TE; Chowdhury NI; Eshaghian PH; Getz AE; Hwang PH; Khanwalkar A; Kimple AJ; Lee JT; Li DA; Norris M; Nayak JV; Owens C; Patel Z; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Turner G; Wang MB; Taylor-Cousar JL; Saavedra M
    Int Forum Allergy Rhinol; 2024 Apr; 14(4):807-818. PubMed ID: 37725072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of noticeable symptom improvement despite sub-MCID change in SNOT-22 score after treatment for chronic rhinosinusitis.
    Phillips KM; Hoehle LP; Caradonna DS; Gray ST; Sedaghat AR
    Int Forum Allergy Rhinol; 2019 May; 9(5):508-513. PubMed ID: 30597742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between cystic fibrosis genotype and sinus disease severity in chronic rhinosinusitis.
    Abuzeid WM; Song C; Fastenberg JH; Fang CH; Ayoub N; Jerschow E; Mohabir PK; Hwang PH
    Laryngoscope; 2018 Aug; 128(8):1752-1758. PubMed ID: 29193105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
    Chun SW; Somers ME; Burgener EB
    Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.
    DiMango E; Overdevest J; Keating C; Francis SF; Dansky D; Gudis D
    J Cyst Fibros; 2021 May; 20(3):460-463. PubMed ID: 32694034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper Airway Disease in Adults with Cystic Fibrosis in the Era of CFTR Modulators.
    Uyttebroek S; Dupont L; Jorissen M; Van Gerven L
    Laryngoscope; 2023 Nov; 133(11):2898-2909. PubMed ID: 36912358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.